Movetis specialise in gastrointestinal products and Shire hopes the acquisition will give them access to Movetis’ constipation treatment Resolor. Resolor is approved for sale in 30 European countries including the UK. Shire estimates Resolor will sell EUR300 million a year in Europe at its peak, although analysts at Jefferies and Edison Investment Research said they’re more cautious on the drug’s potential.
Under the terms of the deal, Shire is offering 19 euros for each share in Movetis. Speaking of the acquisition, a spokesperson from Shire stated the deal brings to the firm “world-class R&D talent and a promising GI pipeline, including two projects in early clinical development and several pre-clinical leads.”
Are you looking for your next position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs now.